Ranomics

Ranomics is a biotechnology firm specializing in advanced cell and protein engineering solutions for life sciences. It provides tailored services designed to overcome research challenges and facilitate the development of innovative biologic products. Ranomics operates in Mississauga, Canada, focusing on biotechnology solutions. The company was founded by Leo Wan, who has a history in entrepreneurial ventures.

Ranomics has raised USD 1. 6 mn in Seed funding from SOSV as of September 2016, which constitutes the total amount raised across its four deals. Ranomics specializes in biotechnology solutions with a focus on advanced cell and protein engineering services tailored for the life sciences and biotechnology sectors. Their core offerings include the development of custom DNA variant libraries, high-throughput screening platforms, and expert solutions for generating and optimizing microbial, fungal, and mammalian cells.

These services are designed to address critical research hurdles faced by clients, facilitating the development of next-generation biologic products. Ranomics serves a diverse clientele, including over 100 leading biotechnology companies and institutions globally, who require expertise in protein design, optimization, and functional assay development. The company operates across various geographical markets, with a significant presence in North America, Europe, and Asia, aiming to empower partners to innovate with speed and precision. Ranomics generates revenue primarily through bespoke contracts with clients in the biotechnology sector, focusing on project-based engagements that often involve ongoing partnerships.

The firm provides tailored services that may include subscriptions for access to their high-throughput screening platform or fee-for-service agreements for specific engineering tasks. These transactions typically involve detailed discussions with clients to understand their unique requirements, leading to customized solutions that align with their research goals. While specific pricing plans for individual services are not disclosed, the company's offerings encompass a range of protein and cell engineering services, catering to various research and therapeutic needs in the biotechnology market. Looking ahead, Ranomics plans to introduce new products aimed at enhancing their cell and protein engineering capabilities.

The company is targeting expansion into additional markets in Europe and Asia by 2025. The recent Seed funding of USD 1. 6 mn will support these initiatives, enabling the development of innovative solutions and the enhancement of their service offerings.